Literature DB >> 8793267

Wegener's granulomatosis overlapped with Takayasu arteritis.

S Yamasaki1, K Eguchi, Y Kawabe, T Tsukada, S Nagataki.   

Abstract

A 27-year-old woman presented with destructive scleritis of the left eye with subcutaneous haemorrhage and swelling of the lower eyelid. She had experienced recurrent nasal bleeding for the last six years, and chronic sinusitis resulting in the destruction of the nasal septum and left maxillary sinus. Nasal mucosal biopsies demonstrated granuloma formation with no evidence of vasculitis. The level of serum cytoplasmic anti-neutrophil cytoplasm antibody (c-ANCA) was significantly increased. Furthermore, multiple sites of complete occlusions were detected in the left subclavian and common carotid arteries by subtraction angiography and MRI. We describe a case of Wegener's granulomatosis overlapped with Takayasu arteritis, which, to our knowledge, has not been previously reported.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793267     DOI: 10.1007/bf02229714

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  ANCA and infection.

Authors:  W H Schmitt; E Csernok; W L Gross
Journal:  Lancet       Date:  1991-06-08       Impact factor: 79.321

2.  Computed tomography of lethal midline granuloma. 5 case reports.

Authors:  S Ovtchinnikoff; D Blin; J P Rouanet; F M Lopez; A Dubois
Journal:  Eur J Radiol       Date:  1988-08       Impact factor: 3.528

3.  Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis.

Authors:  C O Savage; C G Winearls; S Jones; P D Marshall; C M Lockwood
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

4.  Polyangiitis overlap syndrome. Classification and prospective clinical experience.

Authors:  R Y Leavitt; A S Fauci
Journal:  Am J Med       Date:  1986-07       Impact factor: 4.965

5.  Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen.

Authors:  J Lüdemann; B Utecht; W L Gross
Journal:  J Immunol Methods       Date:  1988-11-10       Impact factor: 2.303

6.  Diagnostic specificity of anti-neutrophil cytoplasmic antibodies (ANCA) in otorhinolaryngological diseases.

Authors:  S Fukase; N Ohta; K Inamura; Y Kimura; M Aoyagi; Y Koike
Journal:  Acta Otolaryngol Suppl       Date:  1994

7.  "False positive" perinuclear and cytoplasmic anti-neutrophil cytoplasmic antibody results leading to misdiagnosis of Wegener's granulomatosis and/or microscopic polyarteritis.

Authors:  A Davenport
Journal:  Clin Nephrol       Date:  1992-03       Impact factor: 0.975

8.  Anti-neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection.

Authors:  R J Klaassen; R Goldschmeding; K M Dolman; A B Vlekke; H M Weigel; J K Eeftinck Schattenkerk; J W Mulder; M L Westedt; A E von dem Borne
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

9.  Centrofacial malignant granulomas. Clinicopathologic study of 40 cases and review of the literature.

Authors:  C Grange; J Cabane; A Dubois; M Raphaël; G Chomette; G Lamas; P Godeau; B Meyer; J C Imbert
Journal:  Medicine (Baltimore)       Date:  1992-07       Impact factor: 1.889

10.  Takayasu arteritis. A study of 32 North American patients.

Authors:  S Hall; W Barr; J T Lie; A W Stanson; F J Kazmier; G G Hunder
Journal:  Medicine (Baltimore)       Date:  1985-03       Impact factor: 1.889

View more
  2 in total

1.  Takayasu disease on the centenary of its discovery.

Authors:  Kazuhisa Sugiyama; Shigeyuki Ijiri; Shigeki Tagawa; Koichi Shimizu
Journal:  Jpn J Ophthalmol       Date:  2009-03-31       Impact factor: 2.447

2.  Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature.

Authors:  Julio A Chirinos; Leonardo J Tamariz; Gilberto Lopes; Freddy Del Carpio; Xiaohong Zhang; Clara Milikowski; Daniel M Lichtstein
Journal:  Clin Rheumatol       Date:  2004-01-13       Impact factor: 3.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.